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Abstract
Background: Dual-energy computed tomography (DECT) is a new diagnostic tool for gout, but its sensitivity has
not been established. Our goal was to assess the sensitivity of DECT for the detection of monosodium urate (MSU)
deposits in non-tophaceous and tophaceous gout, both at the level of the patient and that of the individual joint
or lesion.
Methods: DECT was performed on 11 patients with crystal-proven non-tophaceous gout and 10 with tophaceous
gout and included both the upper and lower extremities in 20/21 patients. DECT images were simultaneously
acquired at 80 and 140 kV and then processed on a workstation with proprietary software using a two-material
decomposition algorithm. MSU deposits were color coded as green by the software and fused onto grey-scale CT
images. The number and location of these deposits was tallied independently by two DECT-trained radiologists
blinded to the clinical characteristics of the patient. Sensitivity of DECT was defined as the proportion of patients
with a confirmed diagnosis of gout which was correctly identified as such by the imaging technique. All patients
provided informed consent to participate in this IRB-approved study.
Results: MSU deposits were detected by DECT in ≥1 joint area in 7/11 (64 %) patients with non-tophaceous gout, but
were only detected in 3/12 (25 %) joints proven by aspiration to be affected with gout. Inclusion of the upper extremity
joints in the scanning protocol did not improve sensitivity. All 10 patients with tophaceous gout had MSU deposits
evident by DECT. The sensitivity of DECT for individual gouty erosions was assessed in 3 patients with extensive foot
involvement. MSU deposits were detected by DECT within or immediately adjacent to 13/26 (50 %) erosions.
Conclusions: A DECT protocol that includes all lower extremity joints has moderate sensitivity in non-tophaceous and
high sensitivity in tophaceous gout. However, DECT has lower sensitivity when restricted to individual crystal-proven
gouty joints in non-tophaceous disease or individual erosive lesions in tophaceous gout. The detection of MSU deposits
by DECT relates to their size and density and the detection parameters of the DECT scanner and adjustment of the latter
might improve sensitivity.
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Background
Gout is an inflammatory arthritis characterized by the
deposition of monosodium urate (MSU) crystals in
joints, cartilage, and soft tissues [1]. The untreated dis-
ease can lead to formation of tophi, chronic synovitis,
and joint damage [1, 2]. Thus, the establishment of a
diagnosis and initiation of therapy early in disease are
essential to the maintenance of normal function and
quality of life. Demonstrating MSU crystals in the joint
fluid or in a tophus is the gold standard for gout diagno-
sis. However, many health care providers do not perform
arthrocenteses and the identification of MSU crystals
can be challenging, especially in early disease. In the ab-
sence of MSU crystal demonstration in joint or tophus
aspirates, clinical, radiographic, and laboratory criteria
can be helpful in diagnosis. However, characteristic
radiographic findings are only seen late in the disease,
including “punched-out” erosions with overhanging
edges and sclerotic margins, often in association with
asymmetric soft tissue masses [3, 4]. Various advanced
imaging techniques are being utilized, including ultra-
sonography with power Doppler, magnetic resonance
imaging (MRI), and conventional computed tomography
(CT). Each has their unique advantages and disadvan-
tages. However, none are specific enough to facilitate or
confirm a diagnosis of gout [5]. Dual-energy CT (DECT)
is a new technique that allows identification of MSU
crystal deposits. With this imaging methodology, the
compositions of different tissues are determined by ana-
lyzing the difference in attenuation in a material exposed
simultaneously to two different X-ray spectra. It has high
accuracy and sensitivity for the identification of MSU
and calcium kidney stones [6]. Whereas its sensitivity
has been reported to be 100 % for clinically-overt
tophaceous disease [7–9], its sensitivity has not been
fully established for non-tophaceous disease where its
diagnostic utility would be the greatest.
Our goal was to assess the sensitivity of DECT for the
detection of monosodium urate (MSU) deposits in non-
tophaceous and tophaceous gout, both at the level of the
patient and that of the individual joint or lesion.
Methods
Study patients
We studied 21 patients with gout as defined by the
American College of Rheumatology preliminary criteria
[10]. With one exception, all patients were recruited
from the clinical practice of one of the authors (ANB)
and underwent a comprehensive musculoskeletal exam-
ination at the time of recruitment. The patients included
1) 11 with non-tophaceous gout, defined by the demon-
stration of MSU crystals on a joint aspirate [performed
in 10 of the 11 patients by one of the authors (ANB)]
and the absence of tophi on physical examination or
erosions on available radiographs and 2) 10 with tophac-
eous gout, defined by one or more of the following: the
presence of palpable tophi (n = 5), the presence of char-
acteristic radiographic erosions (n = 7), or gross MSU
deposits in a surgical specimen (n = 3).
The Johns Hopkins Medicine Institutional Review
Boards approved the study. All patients provided written
informed consent before inclusion in the study.
Study protocol
Each patient underwent DECT of their hands, wrists, el-
bows, knees, ankles, and feet using the imaging protocol
described below. The initiation of urate-lowering therapy
(ULT) was not withheld in treatment-naïve patients,
although the scan was completed as soon as possible after
ULT was initiated. Each patient underwent a comprehen-
sive musculoskeletal examination. Clinical data obtained
for this study included demographics (age, gender, ethni-
city), gout history (duration of disease, therapeutic inter-
ventions, frequency of gout flares), arthrocentesis if the
disease was not previously crystal-proven, radiographs
performed as part of the clinical assessment, and labora-
tory evaluation including serum urate levels.
Dual-energy computed tomography protocol
DECT images were obtained of the four limbs scanned
in pairs: the hands/wrists, feet/ankles, elbows, and knees.
With each scan, the patient was positioned so that the
relevant joints were in a central location within the dual
energy field. Each joint area had a scan field which en-
sured that all articulations were visualized in full and in-
cluded a minimum of 4 cm of adjacent extremity for the
elbow, knees, wrists, and ankles. Scans were performed
using a dual-source DECT scanner (SOMATOM Defin-
ition Flash Dual-Source CT scanner; Siemens Health-
care, Forchheim, Germany). Parameters were 80/Sn140
kVp and 211 mAs for tube A with tube B automatically
adjusted to maintain a 2:1 ratio. Collimation of 0.6 mm
was reconstructed to yield a 0.75-mm slice thickness. A
material decomposition algorithm was performed on a
multi-modality workspace (SW-Version VE52 Siemens
Healthcare) using Siemens syngo.via dual-energy soft-
ware package (SW-Version VA20). The material-specific
difference in attenuation of urate between the two en-
ergy levels at 80- and Sn140-kV allowed accurate detec-
tion of MSU, which was then color coded as green and
fused onto the standard greyscale CT image. These
could be reviewed as both 2D cross-sectional and 3D
surface rendered images. The threshold ratio parameter
was set at 1.36, with a range of Hounsfeld units of 150 –
500 HU.
Each DECT scan was read by two of three musculo-
skeletal or CT radiologists (EKF, JAC, or UT, with 32,
16, and 1 years of experience, respectively) and scored
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with respect to the presence and number of MSU de-
posits at each joint. For cases in which a discrepancy
existed, agreement was reached by consensus. These ra-
diologists were blinded to the clinical characteristics of
the patients and trained to exclude known artifacts, in-
cluding those related to nailbeds, skin, metal prostheses,
and beam hardening, from their analyses [11].
Statistical analysis
Descriptive statistics were used to characterize the base-
line features of the cohort. Proportions were used to
summarize categorical variables and median [range] or
mean [standard deviation] for continuous variables. The
Wilcoxon rank-sum test was used to compare continu-
ous variables and the two-sided Fisher exact test was
used to compare categorical variables. Correlations be-
tween continuous variables were tested using the Spear-
man rank correlation coefficient. Sensitivity of DECT
was defined as the proportion of patients with a con-
firmed diagnosis of gout (or specific joint involved by
gout) which was correctly identified as such by the im-
aging technique. P values less than 0.05 were considered
statistically significant. Analyses were conducted using
JMP (Version 11, SAS Institute Inc., Cary, NC).
Results
Demographic and clinical characteristics
The demographic and clinical characteristics of the pa-
tients at the time of DECT are summarized in Table 1.
The study patients included 17 men and four women
with a median age of 59 years (range, 43–89 years).
There was no significant difference in age between the
patients with non-tophaceous and tophaceous gout. The
median duration of gout was 0.8 years (range 0.2-13
years) for the non-tophaceous gout patients and
10.2 years (range 1–28 years) for those with tophaceous
gout. Among the 11 non-tophaceous gout patients,
seven had had gout for less than one year and nine had
had more than one gout attack. The maximum recorded
serum urate value was higher for the tophaceous than
the non-tophaceous gout patients, a difference that did
not reach statistical significance (median value, 594.8 vs
529.4 μmol/L, p = 0.18).
Among the 11 non-tophaceous gout patients, MSU crys-
tals were demonstrated in 12 joint aspirates, including
those of the 1st metatarsophalangeal (n = 7), knee (n = 2),
ankle (n = 2), and metacarpophalangeal (n = 1) joints
(Table 2). The median interval between these joint aspira-
tions and DECT was 37 days (range, 21 – 149). At the time
of DECT, nine of these 11 patients were on ULT with a me-
dian duration of 41 days (range 6–126 days). Serum urate
values obtained within 30 days of DECT were < 6 mg/dl in
three of eight patients.
Among the 10 tophaceous gout patients, five had palp-
able tophi, three with associated radiographic erosions
and one with tophaceous material in a surgical specimen
(Table 3). The remaining five patients had tophaceous
material in a surgical specimen (n = 2) or characteristic
erosions on radiographs (n = 4). Seven of the 10 patients
with tophaceous gout had had their diagnosis confirmed
by microscopic demonstration of MSU crystals.
DECT scanning in non-tophaceous gout
Among the 11 patients with non-tophaceous gout, seven
(64 %) had MSU deposits detected by DECT of both
upper and lower extremity joints (Table 2). The MSU
deposits were present in only three of the 12 joints
(25 %) shown to have MSU crystals by polarized light
Table 1 Characteristics of non-tophaceous and tophaceous
gout patient groups
Non-tophaceous Tophaceous
Number of patients 11 10
Age, years; median (range) 64 (43–72) 56 (49–89)
Male; number (%) 9 (82) 8 (80)
Caucasian; number (%) 9 (82) 8 (80)
Duration of gout, years; median
(range)
0.8 (0.2-13) 10.2 (1–28)
Glomerular filtration rate
<60 ml/min; number (%)
2 (18) 5 (50)
BMI, kg/m2; mean ± SD 29.8 ± 4.0 30.0 ± 3.2
Maximum serum urate
(μmol/L), median (range)
529.4 (339.0-814.9) 594.8 (458.0-850.6)
Urate-lowering therapy at
time of scan, number (%)
9 (82) 7 (70)
Table 2 Results of DECT scanning in patients with non-
tophaceous gout
Patient Distribution of MSU deposits detected by DECT
scanning
Any joint Joint shown to have MSU crystals by
aspiration
1 - - First MTP
2 + - First MTP
3 - - First MTP
4 + + Knee
5 - - Ankle
6 + - First MTP
7 + - First MTP
8 + + Knee
9 - - First MTP
10 + + ankle
- 1st MTP
11 + - MCP
Overall sensitivity 7/11 (64 %) 3/12 (25 %)
Baer et al. BMC Musculoskeletal Disorders  (2016) 17:91 Page 3 of 9
microscopic analysis of aspirated material. MSU deposits
were present in the elbows of three patients, but in each
of these they were also found in one or more lower ex-
tremity joints.
In a comparison of the patients with and without
MSU deposits by DECT, the median age of the seven pa-
tients with deposits was 57 years and that of the four pa-
tients without deposits was 66 years (p = 0.07, Wilcoxon
rank sum test). There were no significant differences in
duration of clinical gout or maximum serum urate value
between the two groups. Among the nine patients on
ULT at the time of the scan, there was no significant dif-
ference in the duration of this therapy between the seven
with and the two patients without MSU deposits.
The number of MSU deposits ranged from 1–15 (median
3) among the seven patients with positive DECT. The num-
ber of these deposits did not correlate significantly with the
maximum serum urate level.
DECT scanning in tophaceous gout
MSU deposits were evident by DECT in each of the 10
patients (100 %) with tophaceous gout (Table 3). We
sought to determine the correlation between MSU de-
posits on DECT with tophi evident by clinical examin-
ation or by the presence of characteristic erosions on
radiographs or CT images. Of the five patients with
palpable tophi, a correlative analysis could be performed
on three (one patient had his solitary tophus surgically
excised and the other had DECT of only the lower ex-
tremities). In these three patients (numbers 15, 19, 20),
there were 25 discrete palpable tophi. Corresponding
MSU deposits were detected with DECT in 19 (76 %).
An example of this is shown in Fig. 1. This patient had
soft tissue masses around the metacarpophalangeal,
proximal interphalangeal and distal interphalangeal
joints of his hand, evident both by palpation and by 3D-
volume rendering of the CT images. MSU deposits












Site of tophi DECT MSU
deposit at site
12 No Yes Erosions on
radiograph
Left 1st MTP +





Right 2nd MTP +
14 No Yes Erosions on
radiograph
Right 1st MTP -
15 Yes Yes Palpable tophi Right olecranon bursaLeft olecranon bursa ++
Erosions on
radiograph
Right 1st MTP +
16 Yes Yes Surgical
specimen
Right peroneus tendon -
17 Yes Yes Palpable tophi Dorsum right long finger PIPDorsum right little finger PIP Upper extremity
DECT not done
18 Yes Yes Erosions on
radiograph
Right carpusLeft ring finger PIP --
19 No Yes Palpable tophi Right Olecranon bursaLeft olecranon bursaLeft ulnar styloidDorsum left ring
finger MCPRight thumb padVolar left little finger PIPRight index fingertip
padRight 1st MTPLeft 1st MTP
-+--+-+++
20 Yes Yes Palpable tophi Left thumb MPLeft little MCPLeft index PIPLeft long PIP radial aspectLeft ring
PIPLeft little between PIP/DIP dorsalRight index PIPRight little DIPRight long






Right carpusRight index PIPRight little DIP +++
21 Yes Yes Surgical
specimen
Left 1st MTP +
Erosions on
radiograph
Left 1st MTP +
Palpable tophus Left 1st MTP +
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evident by DECT largely conformed to these soft tissue
masses, but were sparse in some affected joints and ab-
sent in others (e.g. little finger DIP and long finger PIP
joints).
Ten discrete osseous erosions were evident on radio-
graphs obtained on affected joints of seven patients prior
to DECT. MSU deposits were evident at the site of seven
of these erosions. An example of metatarsal head erosion
not associated with MSU deposits by DECT is shown in
Fig. 2. In this patient, ultrasonography demonstrated
fluffy hyperechoic material in the synovial space, sug-
gestive of tophaceous material.
Three patients had extensive erosions in their feet, evi-
dent by CT and defined by a well-defined cortical break
and overhanging edges. At the time of DECT scan, two
had initiated urate-lowering therapy 34–100 days before
the scan, but none of the three had a serum urate level
<6.8 mg/dl. By fusing the dual-energy processing with
the CT images, we tabulated the number of erosions
with and without corresponding MSU deposits in the
erosion cavity or in the surrounding soft tissue mass.
Among these three patients, there were 26 erosions, only
13 (50 %) of which had associated MSU deposits. This
failure to detect MSU deposits could not be overcome
by changing the lower limit of the density threshold of
the DECT from 150 to 135 Hounsfield units. An ex-
ample of a large erosion evident by CT and lacking asso-
ciated MSU deposits is shown in Fig. 3.
Discussion
The diagnostic utility of DECT in the evaluation of arth-
ritis hinges on its ability to detect MSU deposits in pa-
tients with various stages of gout. In the current study,
we compared the sensitivity of DECT in patients with
crystal-proven, non-tophaceous gout and those with
tophaceous gout, with or without radiographic erosions.
In our 11 patients with non-tophaceous gout, DECT of
joints in all four extremities demonstrated MSU deposits
in seven, equating to an overall sensitivity of 64 %. Im-
portantly, these deposits were only detected in three of
12 (25 %) joints shown to have MSU deposits by aspir-
ation and polarized light microscopic analysis of the syn-
ovial fluid or soft tissue material. In this small series of
seven non-tophaceous gout patients with MSU deposits
detected by DECT, inclusion of the upper extremities in
the scanning protocol served to identify MSU deposits
in the elbows of three, but each had concomitant de-
posits in their lower extremities. Thus the sensitivity of
DECT was not increased by the inclusion of the upper
extremities but was increased by inclusion of all lower
extremity joints.
Our protocol for DECT of both the upper and lower
extremities identified MSU deposits in each of our 10
patients with tophaceous gout. This 100 % sensitivity of
DECT for tophaceous gout is consistent with three other
studies [7–9]. However, this study highlights the limita-
tions of DECT in identifying tophaceous deposits.
Fig. 1 Patient 20. Large tophi are evident in the fingers with 3D volume rendering of the 2-D CT images, using proprietary software for the digital
reconstruction and application of colors and varying degrees of transparency to the tissues panel (a). With DECT scanning panel (b), MSU deposits
(evident by their green coding) conform to the areas of tophaceous deposits, but are sparse in some affected areas and absent in others (e.g. little finger
DIP and long finger PIP)
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Specifically, there were notable examples where MSU
deposits could not be detected in areas of tophaceous
deposits, either judged clinically by physical examination
or by radiographic, ultrasonographic, or CT imaging.
This failure to detect MSU deposits in sites of tophi could
not be overcome by a change in detection thresholds of
the DECT imaging software. Thus, there may be limita-
tions in the sensitivity of DECT for defining gout as the
etiology for individual erosions or periarticular soft tissue
masses.
The sensitivity of DECT in crystal-proven, non-
tophaceous gout has been evaluated in three other
Fig. 2 Patient 14. Erosion of distal right metatarsal head, imaged by radiograph (panel (a), arrow), ultrasound (panel (b), arrow), CT (panel (c), arrow)
and DECT (panel (d), arrow). Fluffy, hyperechoic material is evident in the synovial space on ultrasound (panel (b), arrow). Note the absence of any
green pixellated areas (MSU deposits) in panel (d). The DECT scan was positive for MSU deposits in the left distal metatarsal head (not shown)
Fig. 3 Patient 15. There is a large erosion of the dorsal navicular bone, seen on the coronal and sagittal CT images (panels (a) and (b), red arrows) but
no corresponding green-coded (MSU) deposits in or around the erosion on the DECT images (panels (c-d))
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studies, with reported sensitivities ranging from 79–90 %
[12–14]. In these studies, DECT was restricted to the
feet [13], the clinically affected joint [12], or the most
prominently involved joint regions [14]. The sensitivity
of DECT for the diagnosis of non-tophaceous gout was
lower in our series of patients, particularly when judged
by the detection of MSU deposits in the joints from
which MSU crystals were detected by joint aspiration.
There are several potential reasons for the lower sensi-
tivity noted in our study. First, we may have included pa-
tients with a shorter duration of gout or a lesser degree
of hyperuricemia, leading to MSU crystal deposition
below the threshold of detection of DECT. The reported
sensitivity of DECT for the detection of MSU deposits is
proportional to the stage of gout, being 0.03-24 % in
asymptomatic hyperuricemia [13, 15], 79–80 % in pa-
tients with short-duration acute gout [12, 13], 84 % in
long-duration (≥3 years) acute gout [13] and 100 % in
tophaceous gout [7–9]. The limit of detection of DECT
is generally considered to be 2 mm, so microscopic tophi
may be missed [16]. The mean duration of gout was
shorter in our subjects compared to the participants of
two other studies where these data are provided
(3.1 years in our study compared to 3.8-11 years in the
other studies) [13, 14]. In the study of Manger et al.,
only two of four patients presenting with their first gout
flare had DECT evidence of MSU deposition. The mean
serum urate values were comparable in our subjects to
those of the other three studies, so an effect of hyperuri-
cemia severity could not be assessed. Second, our study
protocol allowed patients to initiate ULT before DECT.
Nine of our 11 subjects with non-tophaceous gout were
on ULT for a median of 35 days (mean 1.5 months).
Eight of these had a serum urate measured within 30 days
of DECT and all but three had a serum urate <6 mg/dl.
However, 82 % of subjects in the study of Dalbeth et al.
were on ULT for an average of 34 months [13]. Similarly,
MSU deposits were detected in 37 of 40 gout patients stud-
ied by Choi et al., despite the fact that 35 had been treated
with ULT [17]. The rate of dissolution of MSU deposits has
been shown to be slow in patients on appropriately-dosed
xanthine oxidase inhibitor or uricosuric therapy, as mea-
sured by clinical exam [18] and by DECT [9, 19]. The size
of subcutaneous tophi, measured with calipers, did not
change significantly over a one-year period in a clinical trial
comparing febuxostat and allopurinol, despite
normalization of the serum urate [20]. Third, our imaging
parameters may have been different from those of other in-
vestigators, although we used parameters established by the
manufacturer as optimal for gout imaging.
The failure of DECT to detect MSU crystal deposits at
sites of tophi evident by physical or pathologic examin-
ation or other imaging methods has been noted by other
investigators. Although DECT identified four times more
urate deposits than physical examination in the study of
Choi et al., there were two patients in whom palpable
tophi did not have a corresponding MSU deposit by
DECT [8]. Glazebrook et al. reported a patient with an
inflamed wrist, small erosions at the head of the third
metacarpal, and negative DECT but evidence of MSU
crystals by joint aspiration and synovial biopsy [16]. In a
study correlating structural joint damage on radiography
of the feet with DECT MSU crystal deposition, Dalbeth
et al. found MSU deposits in 112/262 (43 %) joints with
radiographic erosions. The prevalence of these deposits
in individual joints correlated positively with the joint
erosion score [7]. In 161 gout patients studied by Hu
et al., MSU deposits were evident by DECT in 121.
Among the 40 with negative DECT, eight had MSU de-
posits evident by conventional CT [21]. Similarly,
McQueen detected tophi by MR but not by DECT in
10/150 joint sites in a study of 10 tophaceous gout pa-
tients [22]. In the study of Huppertz et al. comparing
DECT and ultrasound for the diagnosis of gout in 39 pa-
tients, MSU deposits were detected by US but not by
DECT in three patients [23]. At the level of individual
joints, the disparity was more striking. As an example,
MSU deposits were evident by DECT in 26 % and by
ultrasound in 74 % of the 78 first metatarsophalangeal
joints [23]. Finally, Melzer et al. reported a patient with
tophaceous gout who underwent DECT of her feet one
week before her death [24]. Two large soft tissue tophi,
one around the ventral ankle joint and the other at the
distal left great toe, had minimal to no green-coded im-
ages on DECT. At post-mortem examination, both of
these soft tissue masses were confirmed to be tophi with
a central crystalline core, the latter measuring at least
1 cm in one dimension in each.
There are several explanations for the occasional fail-
ure of DECT to detect MSU deposits at sites of tophi.
Dalbeth et al. noted a linear relationship between ero-
sion size and MSU crystal deposition evident by DECT,
suggesting that the resolution of DECT may not be suffi-
cient to detect small tophi [7]. This issue would apply in
particular to MSU deposits detected by ultrasound but
not by DECT. The parameter ratio for DECT is set by
the manufacturer to optimize differentiation of urate-
and calcium-containing voxels. However, several investi-
gators have shown that the use of a different parameter
ratio can correct previously false-negative DECT scans
for MSU deposits detected by conventional CT [21] or
MR imaging [22]. Finally, DECT may only detect dense
tophi. Lockmann et al. showed that DECT did not detect
MSU crystals in a sample of white synovial fluid contain-
ing a high concentration of these crystals by polarized
light microscopy (i.e. “gout milk”) [25]. In the pathologic
examination conducted by Melzer et al., tophi with a
density throughout most of their volume below 150
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Hounsfield units were not color-coded by the DECT im-
aging software, thereby limiting the sensitivity of DECT
for low-density tophi [24].
Our study was limited by the absence of control sub-
jects to assess specificity of DECT. The small size of our
study did not allow determination of the sensitivity of
DECT for the entire spectrum of non-tophaceous gout,
but served to illustrate the limitations of the technique
in patients with early disease whose diagnosis was con-
firmed by joint aspiration.
Conclusions
In conclusion, a DECT scanning protocol that includes
all lower extremity joints has moderate sensitivity in
non-tophaceous and high sensitivity in tophaceous gout.
However, DECT has lower sensitivity when restricted to
individual crystal-proven gouty joints in non-tophaceous
disease or individual erosive or tophaceous lesions in
tophaceous gout. The detection of MSU deposits by
DECT depends on their size and density and the detec-
tion parameters of the DECT scanner. The latter could
potentially be improved with an adjustment of the pa-
rameters used to both acquire and then process the
DECT images.
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